These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36125701)

  • 41. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.
    Lee SW; Kim SY; Chang SH
    BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
    Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
    Boyce EG; Rogan EL; C Lui M
    Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices.
    Katayama K; Okubo T; Sato T; Kamiya K; Fukai R; Abe S; Ito H; Makino Y; Kamishima T
    Mod Rheumatol; 2016 Nov; 26(6):817-827. PubMed ID: 26915909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
    Burmester GR; Van den Bosch F; Tesser J; Shmagel A; Liu Y; Khan N; Camp HS; Kivitz A
    J Rheumatol; 2024 Jul; 51(7):663-672. PubMed ID: 38621793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADAI5 and flare detection in 200 patients.
    Bossert M; Prati C; Vidal C; Bongain S; Toussirot E; Wendling D
    Joint Bone Spine; 2012 Jan; 79(1):57-62. PubMed ID: 21550283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
    Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E
    Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
    Witte T; Kiltz U; Haas F; Riechers E; Prothmann U; Adolf D; Holland C; Rössler A; Soppa U; Fritz B; Götz K; Krüger K;
    Clin Exp Rheumatol; 2024 Mar; 42(3):726-735. PubMed ID: 37976112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
    Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
    Emery P; Tanaka Y; Bykerk VP; Huizinga TWJ; Citera G; Bingham CO; Banerjee S; Soule BP; Nys M; Connolly SE; Lozenski KL; Zhuo J; Wong R; Huang KG; Fleischmann R
    Rheumatol Ther; 2023 Jun; 10(3):707-727. PubMed ID: 36869251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
    Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.